Clinical trial

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

NCT06265428

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-01-29

PhasePHASE3

Study timeline

Study start (actual)2024-01-29Date precision: day

Registry last updated2025-10-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive Breast Cancerunresolved

Interventions

DB-1303/BNT323DRUG

T-DM1DRUG

Sponsors & collaborators

DualityBio Inc.lead sponsor

BioNTech SEcollaborator

Mapped research locations

GuangzhouGuangdong, China3 BeijingBeijing Municipality, China2 ShanghaiShanghai Municipality, China2 HangzhouZhejiang, China2 NanjingJiangsu, China2 WuhanHubei, China2 JinanShandong, China2 ZhengzhouHenan, China2 HefeiAnhui, China2 ChangshaHunan, China1 ChengduSichuan, China1 TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06265428 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.